Journal of Veterinary Medical Science
Online ISSN : 1347-7439
Print ISSN : 0916-7250
ISSN-L : 0916-7250

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

In vitro efficacy of cephamycins against multiple extended-spectrum β-lactamase-producing Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae isolates from dogs and cats
Mizuki KUSUMOTOYuka KANAOHaruka NARITAMakoto JITSUIKIKeita IYORIManami TSUNOIYuzo TSUYUKIKae TORIIKazuki HARADA
著者情報
ジャーナル オープンアクセス 早期公開

論文ID: 23-0052

この記事には本公開記事があります。
詳細
抄録

The susceptibility of 218 extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae isolates from companion animals to three cephamycins (cefmetazole, flomoxef, and latamoxef) was investigated. Phenotypic testing found 8 of 120 Klebsiella pneumoniae (KP) and 15 of 69 Enterobacter cloacae (EC) isolates were ESBL and AmpC β-lactamase (ABL) co-producers. Isolates of KP, P. mirabilis, and EC that only produced ESBL exhibited susceptibility rates to cefmetazole (95.5%, 82.7%, and 9.3%), flomoxef (99.1%, 96.6%, and 74.0%), and latamoxef (99.1%, 100%, and 100%), respectively. Notably, isolates of KP and EC co-producing ESBL and ABL had significantly lower susceptibility rates to the studied drugs when compared with only ESBL producers. This implies that the in vitro activity of cephamycins against ESBL-producing bacteria can differ depending on ABL production and bacterial species.

著者関連情報
© 2023 by the Japanese Society of Veterinary Science

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top